Natalie Franz1, Hannah Rapp1, Ryan N Hansen2, Laura S Gold3, Christopher H Goss4, Noah Lechtzin5, Larry G Kessler6. 1. Department of Health Services, University of Washington, Seattle, Washington, United States. 2. School of Pharmacy, University of Washington, Seattle, Washington, United States. 3. Department of Radiology, University of Washington, Seattle, Washington, United States. 4. Department of Medicine, University of Washington, Seattle, Washington, United States; Department of Pediatrics, University of Washington, Seattle, Washington, United States. 5. Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States. 6. Department of Health Services, University of Washington, Seattle, Washington, United States. Electronic address: kesslerl@uw.edu.
Abstract
BACKGROUND: Home spirometry with regular symptom assessment is one strategy to track lung health to intervene early in episodes of pulmonary exacerbations (PE). In a multi-center randomized controlled trial home spirometry and symptom tracking demonstrated no significant differences regarding the primary clinical endpoint, FEV1, compared to usual care, but did identify differences in healthcare utilization. We used data from the Early Intervention in Cystic Fibrosis Exacerbation (eICE) study to evaluate whether home monitoring of PE is a cost-minimizing intervention in the context of this randomized trial. METHODS: We reviewed healthcare resource utilization of all 267 eICE participants, including outpatient visits, antibiotics and hospitalizations. Prices were identified in the IBM/Watson MarketScanⓇ Commercial Claims and Encounters Databases and averaged over the 2014-2017 period. Using total healthcare utilization costs, we generated summary statistics by intervention and protocol arm (total cost, mean cost, standard deviation). We performed Welch Two Sample t-tests to determine if total costs and cost by type of utilization differed significantly between groups. RESULTS: Outpatient visit costs were significantly higher by 13% in the Early Intervention (EI) than in the usual care (UC) arm ($3,345 vs. $2,966). We found no significant differences in outpatient antibiotic, hospitalization, or total health care costs between the arms. CONCLUSIONS: Within the context of the eICE trial, outpatient visits were significantly higher in those with experimental home spirometry care, but that did not translate into statistically significant differences of overall health care costs between the two arms.
BACKGROUND: Home spirometry with regular symptom assessment is one strategy to track lung health to intervene early in episodes of pulmonary exacerbations (PE). In a multi-center randomized controlled trial home spirometry and symptom tracking demonstrated no significant differences regarding the primary clinical endpoint, FEV1, compared to usual care, but did identify differences in healthcare utilization. We used data from the Early Intervention in Cystic Fibrosis Exacerbation (eICE) study to evaluate whether home monitoring of PE is a cost-minimizing intervention in the context of this randomized trial. METHODS: We reviewed healthcare resource utilization of all 267 eICE participants, including outpatient visits, antibiotics and hospitalizations. Prices were identified in the IBM/Watson MarketScanⓇ Commercial Claims and Encounters Databases and averaged over the 2014-2017 period. Using total healthcare utilization costs, we generated summary statistics by intervention and protocol arm (total cost, mean cost, standard deviation). We performed Welch Two Sample t-tests to determine if total costs and cost by type of utilization differed significantly between groups. RESULTS: Outpatient visit costs were significantly higher by 13% in the Early Intervention (EI) than in the usual care (UC) arm ($3,345 vs. $2,966). We found no significant differences in outpatient antibiotic, hospitalization, or total health care costs between the arms. CONCLUSIONS: Within the context of the eICE trial, outpatient visits were significantly higher in those with experimental home spirometry care, but that did not translate into statistically significant differences of overall health care costs between the two arms.
Authors: Esi Morgan Dewitt; Chelsea A Grussemeyer; Joëlle Y Friedman; Michaela A Dinan; Li Lin; Kevin A Schulman; Shelby D Reed Journal: Value Health Date: 2012-01-27 Impact factor: 5.725
Authors: Antonia V Bennett; Donald L Patrick; James F Lymp; Todd C Edwards; Christopher H Goss Journal: J Cyst Fibros Date: 2010-12 Impact factor: 5.482
Authors: Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott Journal: Chest Date: 2002-01 Impact factor: 9.410
Authors: Laura S Gold; Donald L Patrick; Ryan N Hansen; Valeria Beckett; Christopher H Goss; Larry Kessler Journal: J Cyst Fibros Date: 2018-08-29 Impact factor: 5.482
Authors: Noah Lechtzin; Nicole Mayer-Hamblett; Natalie E West; Sarah Allgood; Ellen Wilhelm; Umer Khan; Moira L Aitken; Bonnie W Ramsey; Michael P Boyle; Peter J Mogayzel; Ronald L Gibson; David Orenstein; Carlos Milla; John P Clancy; Veena Antony; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2017-11-01 Impact factor: 21.405
Authors: Don B Sanders; Lucas R Hoffman; Julia Emerson; Ronald L Gibson; Margaret Rosenfeld; Gregory J Redding; Christopher H Goss Journal: Pediatr Pulmonol Date: 2010-02
Authors: Jocelyn Choyce; Karen L Shaw; Alice J Sitch; Hema Mistry; Joanna L Whitehouse; Edward F Nash Journal: BMC Pulm Med Date: 2017-01-23 Impact factor: 3.317
Authors: Christopher H Goss; Sonya L Heltshe; Natalie E West; Michelle Skalland; Don B Sanders; Raksha Jain; Tara L Barto; Barbra Fogarty; Bruce C Marshall; Donald R VanDevanter; Patrick A Flume Journal: Am J Respir Crit Care Med Date: 2021-12-01 Impact factor: 21.405